News - Page 189 - Psychedelic Alpha

Introducing The Psychedelic Practitioner, a new publication by Psychedelic Alpha.

Read more about the article Cybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug Applications

Cybin Advances IND-Enabling Studies of Two Psychedelic Molecules, CYB003 and CYB004 for Investigational New Drug Applications

Post published:April 13, 2021
Post category:Press Release

Read more about the article Former GW Pharmaceuticals CFO joins Beckley Psytech’s Board

Former GW Pharmaceuticals CFO joins Beckley Psytech’s Board

Post published:April 13, 2021
Post category:Press Release

Read more about the article PsyBio Therapeutics Announces Application to List on OTCQX

PsyBio Therapeutics Announces Application to List on OTCQX

Post published:April 13, 2021
Post category:Press Release

Read more about the article MINDCURE Announces Partnership with Speak Ai to Enhance iSTRYM, the Company’s Psychedelic Digital Therapeutics Technology Platform

MINDCURE Announces Partnership with Speak Ai to Enhance iSTRYM, the Company’s Psychedelic Digital Therapeutics Technology Platform

Post published:April 13, 2021
Post category:Press Release

Read more about the article Awakn launches Digital unit and signs agreement with the University of Exeter

Awakn launches Digital unit and signs agreement with the University of Exeter

Post published:April 12, 2021
Post category:Press Release

Read more about the article GH Research Announces Closing of $125 Million Oversubscribed Series B Financing

GH Research Announces Closing of $125 Million Oversubscribed Series B Financing

Post published:April 12, 2021
Post category:Press Release

Read more about the article Psychedelic Bulletin: CA Decrim. Bill Passes Key Committee; MindMed Publishes MDMA Dosing Study; atai Acquires DTx Company

Psychedelic Bulletin: CA Decrim. Bill Passes Key Committee; MindMed Publishes MDMA Dosing Study; atai Acquires DTx Company

Post published:April 9, 2021
Post category:Psychedelic Bulletin

Read more about the article Former FDA Psychiatry Division Director Dr. Thomas Laughren Joins BetterLife as Regulatory Advisor

Former FDA Psychiatry Division Director Dr. Thomas Laughren Joins BetterLife as Regulatory Advisor

Post published:April 8, 2021
Post category:Press Release

Read more about the article MINDCURE Announces Additional Equity Investment in ATMA, The First Government Approved Psychedelic Journey Centers In Canada; MCUR President and CEO, Kelsey Ramsden Named to ATMA Board of Directors

MINDCURE Announces Additional Equity Investment in ATMA, The First Government Approved Psychedelic Journey Centers In Canada; MCUR President and CEO, Kelsey Ramsden Named to ATMA Board of Directors

Post published:April 8, 2021
Post category:Press Release

Read more about the article Psychedelic Research Bulletin: March 2021

Psychedelic Research Bulletin: March 2021

Post published:April 7, 2021
Post category:Psychedelics Research Review

End of content

No more pages to load

Psychedelic Alpha

Psychedelic Alpha is an independent newsletter and community that strives to empower a diverse constellation of individuals and organisations with the knowledge, network and nuance to make an impact within the field of psychedelic medicine and beyond

Quick Links

Newsletter

Insights and interviews delivered to your inbox. No spam, just valuable information.